Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Low Cost Stocks to Buy According to Analysts. On September 8, Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) with a price target of $640. The analyst noted that his rating is based on the strong results from Phase 3 trials for the company’s cat and birch allergy antibody cocktails. The results showed significant symptom reduction with key improvements seen in ocular itch, redness, and ...